AMENDMENT TO THE CLAIMS

1. (Currently Amended) A compound of the general formula I

where

 \mathbb{R}^{n} and \mathbb{R}^{n} are each independently selected from hydrogen, halogen, optionally substituted G_{4} G_{6} -alkyl, G_{3} G_{6} -cycloalkyl, G_{2} G_{6} -alkenyl, G_{2} G_{6} -alkynyl, G_{4} G_{6} -alkyloxy, G_{5} G_{6} -cycloalkyl G_{4} G_{4} -alkyloxy and optionally substituted phenyl:

W is O, S or an N-R* group where R* is selected from optionally substituted C_1 - C_6 -alkyl, C_3 - C_6 -cycloalkyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_1 - C_6 -alkoxy, C_3 - C_6 -cycloalkyl- C_1 - C_4 -alkyloxy and optionally substituted phenyl and * denotes the bonding sites;

- -B- is a bond or where R^m and Rⁿ are each independently selected from hydrogen, halogen, optionally substituted C₁-C₆-alkyl, C₃-C₆-cycloalkyl, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₁-C₆-alkoxy, C₃-C₆-cycloalkyloxy, C₃-C₆-cycloalkyl-C₁-C₆-alkyloxy and optionally substituted phenyl, or, when the nitrogen in the A group is bonded to B, may also be a carbonyl group, and * denotes the bonding sites;
- represents a single bond or a double bond;
- $$\begin{split} R^{v},R^{w} & \text{ are each independently hydrogen, halogen, optionally substituted C_{1}-C_{6}-alkyl, C_{1}-C_{6}-alkynyl, C_{3}-C_{6}-cycloalkyloxy,} \\ & \text{ alkoxy, C_{2}-C_{6}-alkenyl, C_{2}-C_{6}-alkynyl, C_{3}-C_{6}-cycloalkyloxy,} \end{split}$$
 - C3-C6-cycloalkyl-C1-C4-alkyloxy or C3-C6-cycloalkyl; or
- R*, R'—are each independently hydrogen, halogen, optionally substituted C₂-C₆-alkyl, C₂-C₆alkoxy, C₂-C₆-alkenyl, C₂-C₆-alkynyl, C₂-C₆-eyeloalkyloxy, C₃-C₆-eyeloalkyl-C₂-C₄alkyloxy or C₂-C₆-eyeloalkyl, or
- R², R⁷, __together with the carbon atoms to which they are bonded, may also form a fused phenyl ring or a fused 5- or 6 membered aromatic heterocycle which has 1, 2, 3 or 4 heteroatoms which are selected from N, O and S, where the fused phenyl ring and the fused aromatic heterocycle may have 1, 2 or 3 substituents which are selected from optionally substituted C₁-C₀-alkyl, CN, OR¹, NR²R³, NO₂ SR⁴, SO₂R⁴, SO₂NR²R³, CONR²R³, COOR⁴, COR⁶, C₁-C₄-haloalkoxy, C₂-C₆-alkenyl, C₂-C₆-alkenyloxy, C₂-C₆-alkenyloxy, C₂-C₆-alkenyloxy and halogen; where

D

 R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are each independently H, optionally substituted C_i - C_6 -alkyl or optionally substituted phenyl, where R^3 may also be a COR 7 group where R^7 is hydrogen, optionally substituted C_i - C_4 -alkyl or optionally substituted phenyl, where R^2 with R^3 may also together form a 5- or 6-membered, saturated or unsaturated carbocycle which may have a heteroatom selected from O, S and NR 8 as a ring member, where R^8 is hydrogen or C_1 - C_4 -alkyl,

is a linear or branched 2- to 10-membered alkylene chain which may have, as chain members, a heteroatom group K which is selected from O, S, S(O), S(O)₂, N-R*, CO-O, C(O)NR*, and/or 1 or 2 nonadjacent carbonyl groups and which may include a cycloalkanediyl group and/or may have a double or triple bond;

ż is a saturated or monounsaturated, monocyclic nitrogen heterocycle having from 5 to 8 ring members or a bicyclic saturated nitrogen heterocycle having from 7 to 12 ring members, where the mono- and the bicyclic nitrogen heterocycle optionally has, as a ring member, a further heteroatom selected from oxygen, sulfur or nitrogen, where the mono- or bicyclic nitrogen heterocycle may be unsubstituted or bears an R* radical, where

$$\begin{split} R^* & \quad \text{is } C_4 \cdot C_{40} \text{-alkyl}, C_3 \cdot C_{40} \text{-alkenyl}, C_4 \cdot C_{40} \text{-alkeyearbonyl}, C_3 \cdot C_{40} \text{-alkylearbonyl}, C_4 \cdot C_{40} \text{-alkylearbonyl}, C_5 \cdot C_{40} \text{-eyeloalkyl}, C_5 \cdot C_{40} \text{-eyeloalkyl}, C_5 \cdot C_{40} \text{-eyeloalkyl}, C_5 \cdot C_{40} \text{-eyeloalkyl}, C_5 \cdot C_{40} \text{-eyeloalkylearbonyl}, C_5 \cdot C_{40} \text{-eyeloalkylearbonyl}, C_5 \cdot C_4 \text{-alkyl}, \\ & \text{phenylearbonyl}, \text{phenylearbonyl} \cdot C_5 \cdot C_5 \text{-alkyl}, \text{phenoxyearbonyl}, \text{phenyl} \cdot C_4 \cdot C_{40} \text{-alkyl}, \\ & \text{alkyloxyearbonyl}, 3 - \text{to } 8 - \text{membered heterocyelylearbonyl} \text{ or } 3 - \text{to } 8 - \text{membered heterocyelylearbonyl} \cdot C_5 \cdot C_6 \text{-alkyl}, \text{ where heterocyelyl in the aforementioned} \end{split}$$

radicals may have one, two or three heteroatoms selected from S, O and N, and

where the last 6 radicals may have, on the heterocycle or on the phenyl ring, 1; 2 or 3 substitutents R^b-which are each independently selected from optionally substituted C_a, C_a-alkyl, C_a, C_a-alkenyl, C_a, C_a-alkynyl, C_a, C_a-eycloalkyl, C_a, C_a-alkyl, C_a-alkyl, C_a-alkyl, C_a-alkyl, C_a-alkyl, C_a-alkyl, C_a-alkyl, C_a-alkyl, C_a-alkyl, C_a

R* is an E-Ar group wherein E is a bond or linear or branched alkylene having from 1 to 4 carbon atoms and in particular (CH₂)_p where p is 0, 1, 2, 3 or 4, and Ar is selected from phenyl, naphthyl and 5- or 6-membered heteroaryl which has one, two or three heteroatoms selected from S, O and N as ring members and which may optionally have 1, 2 or 3 of the aforementioned substituents R^b_which are each independently selected from C₁-C₂-alkyl, C₂-C₄-alkynyl, C₃-C₄-cycloalkyl, C₄-C₄-bicycloalkyl and C₅-C₄-cycloalkyl, C₄-C₄-bicycloalkyl and C₅-C₄-cycloalkyl, C₄-C₄-cycloalkyl, C₄-C₄-bicycloalkyl and C₅-C₄-cycloalkyl.

tricycloalkyl, where the last three groups may optionally be substituted by halogen or C_3 - C_3 -alkyl, halogen, CN, CR^1 , NR^2R^3 , NO_2 , SR^4 , SO_2R^3 , $CONR^2R^3$, $SO_2NR^2R^3$, $COOR^5$, COR^6 , C- COR^6 , S- or G-membered saturated, partly unsaturated or aromatic heterocyclyl having 1, 2 or 3 heteroatoms selected from O, S and N, and phenyl, where phenyl and heterocyclyl in the last two substituents R^b may optionally bear one or two substituents which are each independently selected from C_1 - C_2 -alkyl, C_1 - C_2 -alkoy, NR^2R^3 , CN, C_3 - C_2 -fluoroalkyl and halogen, and where 2 substituents R^b bonded to adjacent carbon atoms of the aromatic radical may together be C_3 - or C_3 -alkylene, or, together with the carbon atoms to which they are bonded, may be a fused-on, unsaturated 5- or 6-membered carbocycle or a 5- or 6-membered heterocycle or

is a saturated monocyclic nitrogen heterocycle having from 5 to 7 ring atoms which

where * denotes the bonding sites to the saturated monoeyelic heterocycle; R* may be the same or different and is as defined for R*, and n is 0, 1, 2 or 3:

where the term "optionally also have 1, 2, 3 or 4 further G_i - G_i -alkyl groups as substituents; where the term "optionally substituted phenyl" in the definition of R^z , R^u , R^v , R^v , R^v , R^v , R^z ,

 C_3 - C_4 -cycloalkyl, C_1 - C_4 -haloalkyl, C_1 - C_5 -alkoxy, OR^{21} , $COOR^{21}$, $NR^{22}R^{23}$, $SO_2NR^{22}R^{23}$, $CONR^{22}R^{23}$, $S-R^{24}$, SOR^{25} , SO_2R^{25} , $OCOR^{26}$ and COR^{26} , where R^{21} to R^{26} are hydrogen, C_1 - C_4 -alkyl, C_1 - C_4 -haloalkyl, C_3 - C_7 -cycloalkyl, benzyl or phenyl;

where the term "optionally substituted alkyl" in the definition of R^a , R^a

$$R = A - D - N Z$$

where R is halogen, an O-R¹ group where R¹ is as defined above, or an O-C(O)R² group where R⁹ is hydrogen, optionally substituted C₁-C₆-alkyl, benzyl or phenyl, where the last two radicals are optionally substituted by one or two radicals which are each independently selected from C₁-C₄-alkyl, OH, C₁-C₄-alkoxy, NR²R³, CN, C₁-C₂-fluoroalkyl or halogen, and the physiologically acceptable acid addition salts of the tautomer I¹.

- 2. (Canceled)
- (Previously Amended) A compound as claimed in claim 1, where D in the formulae I
 and I' is a (CH₂)k group or a C(O)(CH₂)l group, where k is 3, 4, 5 or 6 and I is 2, 3, 4 or 5.
- (Previously Amended) A compound as claimed in claim 1, where A is N-C(O) in which the carbon atom is bonded to the variable B.
 - 5. (Withdrawn) A compound as claimed in claim 4, where B is CH2.

 (Previously Amended) A compound of the general formula I or I' as claimed in claim 1, where is a radical of the formula where

- I is CH₂, CH₂-CH₂ or CH₂-CH₂-CH₂;
- X is CH or N and
- Y is CH₂, CH₂-CH₂ or CH₂-CH₂-CH₂, or Y-X together is CH=C or CH₂-CH=C;
- R^e is hydrogen or C₁-C₄-alkyl.
- 7. (Original) A compound as claimed in claim 6, where J is CH2-CH2 and Y is CH2.
- 8. (Previously Amended) A compound as claimed in claim 6, where X is N.
- 9. (Canceled)
- 10. (Currently Amended) A compound as claimed in-claim 9 claim 1, where E is a bond.
- 11. (Original) A compound as claimed in claim 10, where Ar is phenyl, pyridyl, pyrimidinyl or s-triazinyl, each of which has 1, 2 or 3 of the aforementioned Rb radicals.
 - 12. (Original) A compound as claimed in claim 9, where E is CH2.
- 13. (Original) A compound as claimed in claim 12, where Ar is phenyl, naphthyl, pyridyl, pyridinyl, pyrazinyl, pyridazinyl, thienyl, furyl, pyrrolyl, pyrazolyl, imi-dazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1-oxa-3,4-diazolyl or 1-thia-3,4-diazolyl, each of which is unsubstituted or may have 1, 2 or 3 of the above-mentioned R^b radicals.
 - 14. (Canceled)
 - 15. (Original) A compound of the general formula I-Aa

$$O = A - D - N \longrightarrow R^a$$
 (I-Aa)

where Ra, A, B and D are each as defined in claim 1;

m is 0, 1, 2 or 3;

 R^d are each independently C_1 - C_4 -alkyl, C_1 - C_4 -hydroxyalkyl, C_1 - C_4 -alkoxy- C_1 - C_6 -alkyl, CN, OR^3 , NR^2R^3 , NO_2 , SR^4 , SO_2R^4 , $SO_2NR^2R^3$, $CONR^2R^3$, $CONR^5$, COR^6 , C_1 - C_2 -fluoroalkyl, C_1 - C_2 -fluoroalkoxy, C_2 - C_6 -alkenyl, C_2 - C_6 -alkenyloxy, C_2 - C_6 -alkylyloxy, C_3 - C_6 -cycloalkyl, C_3 - C_6 -cycloalkyl, C_3 - C_6 -cycloalkyl, C_3 - C_6 -alkylyloxy, C_3 - C_6 -alkylyloxy, C_3 - C_6 -alkylyloxy, C_3 - C_6 -cycloalkyl, C_3 - C_6 - C_8

X is CH or N and

Y is CH2, CH2-CH2 or CH2-CH2-CH2 or Y-X together is CH=C or CH2-CH=C;

the physiologically acceptable acid addition salts of this compound and the tautomer of the formula I-A'a

$$R \xrightarrow{B} A - D - N \xrightarrow{J} X - R^{a}$$
 (I-A'a)

where R is as defined in claim 1 and the physiologically acceptable acid addition salts of the tautomer Ia'.

- 16. (Canceled)
- 17. (Previously Amended) A compound as claimed in claim 15, where J is CH_2 - CH_2 and Y is CH_2 -
 - 18. (Previously Amended) A compound as claimed in claim 15, where X is N.

- 19. (Canceled)
- 20. (Currently Amended). A compound as claimed in claim 4915, where E is a bond.
- (Original). A compound as claimed in claim 20, where Ar is phenyl, pyridyl, pyrimidinyl
 or s-triazinyl, each of which has 1, 2 or 3 of the aforementioned R^b radicals.
 - 22. (Original). A compound as claimed in claim 19, where E is CH2.
- 23. (Currently Amended). A compound as claimed in claim 22, where Ar is phenyl, naphthyl, pyridyl, pyridinyl, pyrazinyl, pyridazinyl, thienyl, furyl, pyrrolyl, pyrazolyl, imi-dazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1-oxa-3,4-diazolyl or 1-thia-3,4-diazolyl, each of which is unsubstituted or may have 1, 2 or 3 of the above-mentioned R^b radicals.
 - 24. (Canceled)
- 25. (Previously Amended). A pharmaceutical composition comprising at least one active ingredient which is selected from compounds of the formula I, the tautom-ers of the formula I', the physiologically tolerated acid addition salts of the com-pounds I and the physiologically tolerated acid addition salts of the tautomers of the formula I' as claimed in claim 1, optionally together with physiologically ac-ceptable carriers and/or excipients.
- 26. (Currently Amended). The use of active ingredients which are se-lected from A method for treating a medical disorder selected from the group consisting of Parkinson's disease, schizophrenia, cognitive disturbances, depression, anxiety, addiction, kidney function disturbances, and eating disturbances, said method comprising administering to a subject in need thereof an effective amount of at least one compounds compounds of the formula I, the tautomers of the formula I', the physiologically tolerated acid addition salts of the compounds I and the physiologically tolerated acid addition salts of the formula I' as claimed in claim I for producing a pharmaceutical composition for treating diseases which respond to the influence of dopamine D3 receptor antagonists or agonists.
 - 27. (Canceled)

28. (Canceled)

29. (New) The compound according to claim 15, wherein

J is CH2-CH2;

X is N

Y is CH₂:

and wherein

R^a is a radical E-Ar, wherein E is a bond and Ar is selected from phenyl, pyridyl, pyrimidinyl and s-triazinyl, each of which has 1, 2 or 3 of the aforementioned R^b radicals.

30. (New) The compound according to claim 29, wherein Ra is a radical Ar-1

$$D^1 = \begin{pmatrix} R^f \\ D^2 \end{pmatrix}$$
 D^2
 R^g
 R^g

wherein D1 and D2 are N and D3 is CH and wherein

 R^f and R^g are each independently selected from the following groups: OR^1 , NR^2R^3 , CN, C_1 - C_6 -alkyl which is optionally substituted by OH, C_1 - C_4 -alkoxy, halogen or phenyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_3 - C_6 -cycloalkyl, C_4 - C_{10} -bicycloalkyl, C_6 - C_{10} -tricycloalkyl, where the last three groups may optionally be substituted by halogen or C_1 - C_4 -alkyl, halogen, CN, OR^4 , 5- or 6-membered het-erocyclyl having 1, 2 or 3 heteroatoms selected from O, S and N, and phenyl, where phenyl and heterocyclyl optionally bear one or two substituents which are each independently selected from C_1 - C_4 -alkyl, C_1 - C_4 -alkoxy, NR^2R^3 , CN, C_1 - C_4 -fluoroalkyl and halogen.

31. (New) The compound according to claim 15, which is of the formula I-Aa

wherein E is a bond and Ar is selected from phenyl, pyridyl, pyrimidinyl and s-triazinyl, each of which has 1, 2 or 3 of the aforementioned R^b radicals.

32. (New) The compound according to claim 30, wherein Ar is a radical Ar-1

wherein D1 and D2 are N and D3 is CH and wherein

 R^f and R^g are each independently selected from the following groups: OR^1 , NR^2R^3 , CN, C_1 - C_6 -alkyl which is optionally substituted by OH, C_1 - C_4 -alkoxy, halogen or phenyl, C_2 - C_6 -alkenyl, C_2 - C_6 -alkynyl, C_3 - C_6 -cycloalkyl, C_4 - C_{10} -bicycloalkyl, C_6 - C_{10} -tricycloalkyl, where the last three groups may optionally be substituted by halogen or C_1 - C_4 -alkyl, halogen, CN, OR^1 , 5- or 6-membered heterocyclyl having 1, 2 or 3 heteroatoms selected from O, S and N, and phenyl, where phenyl and heterocyclyl optionally bear one or two substituents which are each independently selected from C_1 - C_4 -alkyl, C_1 - C_4 -alkoy, NR^2R^3 , CN, C_1 - C_2 -fluoroalkyl and halogen.